Tests with low blood volume

Pharmaceutical drug development requires early and comprehensive assessment of intended metabolic interactions versus undesired interferences. The highly flexible ROTEM® technology in combination with its unique set of test assays provides an ideal tool for researchers to study different effects related to the haemostatic balance and coagulation pathways. All tests can be performed with just one hundred microlitres whole blood or plasma.

Support for the development of new preparations

Besides the detection of coagulopathic side effects in different therapeutic applications, the system has been proven to enable detailed dose-response studies for several coagulation factors (e.g., FVIII, FXIII, FVII, PCC, etc.) or anticoagulant substances (e.g., FXa or FIIa inhibitors, heparin, etc.). Owing to its sensitivity and differential diagnostic approach, the development of new preparations such as haemoglobin-based oxygen carriers (HBOC) or volume replacements like plasma-balanced HES can benefit from ROTEM® analysis. It is also an ideal tool for the characterization and quality control of innovative blood products, for example cryo-protected RBC’s, platelets or freeze-dried plasma components.